NCT00340379 Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression Status COMPLETED Phase PHASE2/PHASE3
NCT00338949 Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes Status COMPLETED Phase PHASE4
NCT00338884 Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer Status COMPLETED Phase PHASE2
NCT00332137 Effects of Tolterodine, a Non-Specific Muscarinic Antagonist, on Gastrointestinal Transit in Healthy Subjects Status COMPLETED Phase PHASE2
NCT00331175 Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults Status COMPLETED Phase PHASE1
NCT00330564 Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow Status TERMINATED Phase PHASE2
NCT00329069 The Role of Atorvastatin on Monocyte Function in Patients With Coronary Artery Disease and Hypercholesterolemia Status COMPLETED Phase NA
NCT00329043 Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT00328432 A Study of Women With an Early Diagnosis of Breast Cancer, Taking Celecoxib Between the Biopsy and Lumpectomy/Mastectomy Status COMPLETED Phase PHASE1
NCT00328055 Comparison of an Easy to Read Advance Directive Versus a Standard Advance Directive Status COMPLETED Phase NA
NCT00327691 A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels Status COMPLETED Phase PHASE4
NCT00327470 An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD Status TERMINATED Phase PHASE4
NCT00327418 CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events Status COMPLETED Phase PHASE4
NCT00326326 Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes. Status COMPLETED Phase PHASE2
NCT00324116 Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions Status COMPLETED Phase PHASE4